ADReCS

Pharmaceutical Information

Drug Name	Carboplatin
Drug ID	BADD_D00364
Description	Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage	Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status	approved
ATC Code	L01XA02
DrugBank ID	DB00958
KEGG ID	D01363
MeSH ID	D016190
PubChem ID	426756
TTD Drug ID	D0X7HM
NDC Product Code	0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII	BG3F62OND5
Synonyms	Carboplatin \| cis-Diammine(cyclobutanedicarboxylato)platinum II \| CBDCA \| Paraplatin \| Paraplatine \| Platinwas \| Ribocarbo \| Carboplat \| Neocarbo \| Carbosin \| Carbotec \| Ercar \| JM-8 \| JM 8 \| JM8 \| Nealorin \| NSC-241240 \| NSC 241240 \| NSC241240 \| Blastocarb

Chemical Information

Molecular Formula	C6H12N2O4Pt
CAS Registry Number	41575-94-4
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Complex regional pain syndrome	17.02.07.010; 12.01.12.004	0.000112%		Not Available
Infusion site extravasation	12.07.05.008; 08.02.05.007	0.000280%
Bone marrow failure	01.03.03.005	0.001903%
Soft tissue necrosis	24.04.02.007; 15.03.02.002	0.000112%
Injection site papule	23.03.03.045; 12.07.03.031; 08.02.03.031	0.000168%		Not Available
Cytopenia	01.03.03.012	0.000392%		Not Available
Treatment failure	08.06.01.017	0.001388%		Not Available
Liver injury	09.01.07.022; 12.01.17.012	0.000392%		Not Available
Regurgitation	07.01.07.004	0.000168%		Not Available
Hypertransaminasaemia	09.01.02.005	0.000336%		Not Available
Oropharyngeal discomfort	07.05.05.008; 22.12.03.015	0.000448%		Not Available
Oropharyngeal pain	22.12.03.016; 07.05.05.004	0.000728%
Neurological decompensation	17.02.05.030	0.000112%		Not Available
Vulvovaginal pain	21.08.02.009	0.000112%
Acute kidney injury	20.01.03.016	0.003302%
Hypoxic-ischaemic encephalopathy	24.04.06.021; 22.02.02.011; 17.13.02.006	0.000392%		Not Available
Gastrointestinal tract irritation	07.08.03.008	-	-	Not Available
Posterior reversible encephalopathy syndrome	17.13.02.007	0.000280%
Substance-induced psychotic disorder	12.03.01.053; 19.03.01.007	0.000112%		Not Available
White matter lesion	24.04.06.027; 17.11.01.009	0.000168%		Not Available
Autoimmune haemolytic anaemia	10.04.01.005; 01.06.01.004	0.000448%		Not Available
Genitourinary symptom	21.10.01.014; 20.08.01.008	-	-	Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.000616%
Anal incontinence	07.01.06.029; 17.05.01.021	0.000392%
Ureterolithiasis	20.04.03.003	0.000168%		Not Available
Abnormal loss of weight	14.03.02.019	0.000448%		Not Available
Acute myelomonocytic leukaemia	16.01.05.005; 01.10.05.005	0.000168%		Not Available
Alopecia areata	23.02.02.008; 10.04.02.011	0.000168%		Not Available
Arterial rupture	24.03.02.027; 12.01.11.010	0.000381%		Not Available
Bladder sphincter atony	20.03.03.006; 17.05.01.023	0.000280%		Not Available

The 18th Page First Pre 18 19 20 21 Next Last Total 21 Pages